Shares of Concordia Healthcare Corp. (NASDAQ:CXRX) saw unusually-strong trading volume on Monday . Approximately 4,235,842 shares were traded during trading, an increase of 264% from the previous session’s volume of 1,164,140 shares.The stock last traded at $9.40 and had previously closed at $10.13.

CXRX has been the subject of several research analyst reports. RBC Capital Markets reiterated an “outperform” rating and set a $33.00 price target on shares of Concordia Healthcare Corp. in a report on Monday. TD Securities reiterated a “buy” rating and set a $37.00 price target (down from $45.00) on shares of Concordia Healthcare Corp. in a report on Wednesday, June 29th. Zacks Investment Research downgraded shares of Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a report on Monday, July 18th. CIBC downgraded shares of Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 price target for the company. in a report on Monday. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $73.00 price target on shares of Concordia Healthcare Corp. in a report on Tuesday, June 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $41.48.

The company’s market cap is $449.98 million. The stock has a 50-day moving average price of $18.19 and a 200-day moving average price of $25.19.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its earnings results on Friday, August 12th. The company reported $1.38 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.38. The company had revenue of $231.70 million for the quarter, compared to the consensus estimate of $229.76 million. The business’s revenue was up 208.1% on a year-over-year basis. Equities analysts forecast that Concordia Healthcare Corp. will post $5.73 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.